2026-04-25T05:50:30Z https://www.pub.unibl.org/oai

oai:pub.unibl.org:21494 2025-12-19T04:43:59Z

Article text Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57. Jelena Rožić, Zdenka Gojković, S Jungić, Ivanka Rakita, Ž Vranješ, R Rašeta, G Marić, M Vještica, S Mijatović, Predrag Dašić, M Vižin Jelena Rožić Unknown Zdenka Gojković Unknown S Jungić Unknown Ivanka Rakita Unknown Ž Vranješ Unknown R Rašeta Unknown G Marić Unknown M Vještica Unknown S Mijatović Unknown Predrag Dašić Unknown M Vižin Unknown not applicable 2011 2011 2011 location unknown J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011. 21494 item oai:pub.unibl.org:21494